Supply chains have key role to play in global vaccine equity conversation


Manhattan Associates, Milan, Italy


As we have witnessed over the last two years, when functioning correctly, global supply chains broaden access to critical medicines for billions around the world. Yet any number of situations, from macro events like the ongoing pandemic, the 2010 volcanic eruption in Iceland, geopolitical instability, or simply patient misunderstandings, can lead to expensive and often unnecessary wastage.

The pharmaceutical industry has a complex global supply chain. One that requires regulatory scrutiny, a raft of compliance checks, as well as the challenges associated with transporting products that are often both temperature and humidity sensitive. As the international case for vaccine equity gains momentum, there is a recognition of the need for better distribution of vital medications – particularly in less economically developed countries (1).


Manhattan Associates, explains how modern, connected supply chains can help pharmaceutical companies, NGOs & IGOs to better manage over-the-counter products, reduce wastage and also support global initiatives for more equitable distribution of COVID19 vaccines. 

For many years, waste and inefficiency has been a concern for health services, pharmaceutical providers and governments. In the UK alone, wasted and unused medicine is estimated to cost the NHS £300 million every year – a problem that extends far beyond patient behaviour.


In ensuring vital products are always available at the point of demand, pharma ...